한글목차

세계의 특수 의약품 시장 규모는 2034년까지 CAGR 7.5%로 성장할 것으로 예측됩니다.

디지털 기술과 AI가 업계의 성장을 촉진

특수 의약품 분야에서 디지털 기술과 AI의 통합은 큰 변화를 약속하고 있습니다. 첨단 IT 플랫폼과 AI 기반 솔루션을 도입함으로써 기업은 업무 효율성을 높이고, 바이오의약품 시장 출시 시간을 단축하며, 전례 없는 수준의 혁신을 촉진할 수 있습니다. 자동화된 워크플로우와 실시간 데이터 분석을 통해 민첩한 의사결정을 내릴 수 있고, 새로운 시장 기회를 빠르게 활용할 수 있습니다.

강력한 IT 인프라는 클라우드 기반 솔루션을 활용하여 안전한 데이터 공유와 합리적인 지식 교환을 실현하고, 전 세계 팀과 이해관계자간의 원활한 협업을 촉진합니다. 개인화된 대시보드와 모바일 애플리케이션은 실시간 인사이트와 실행 가능한 인텔리전스를 제공해 고객 참여도를 높입니다. 이러한 사전 예방적 접근 방식은 고객과의 관계를 강화할 뿐만 아니라 역동적인 시장에서 기업의 경쟁력을 강화합니다.

또한 디지털화는 예측 분석과 머신러닝 알고리즘을 통해 공급망 관리와 자원 배분을 최적화하여 보다 원활한 운영과 비용 효율을 보장할 수 있습니다. 가상 임상시험 및 원격의료 플랫폼은 디지털 발전을 활용하여 환자 모집, 참여 및 전체 시험 결과를 개선하고 궁극적으로 혁신적인 치료법 시장 출시를 가속화할 수 있습니다.

특수 의약품 시장은 디지털 전환을 통해 새로운 차원의 효율성, 혁신, 시장 확대를 달성할 수 있는 기회를 맞이하고 있습니다. 이러한 기술을 도입하는 것은 현재 수요를 충족시킬 뿐만 아니라, 기업이 미래의 도전에 민첩하게 대응할 수 있도록 준비하여 탄력적이고 미래지향적인 특수 의약품의 전망을 형성할 수 있도록 도와줄 것입니다.

세계의 특수 의약품 시장을 조사했으며, 시장 개요, 시장 성장에 대한 영향요인 및 시장 기회 분석, 시장 규모 추이·예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 리포트 개요

제2장 개요

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
• 영향 분석
  • 시장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• 공급망 분석
• 규제 프레임워크
• 신흥 시장과 메가동향
• Porter's Five Forces 분석
• PEST 분석

제4장 특수 의약품 시장 분석 : 투여 경로별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이·예측
• 경구
• 비경구
• 경장
  • 시장 규모 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제5장 특수 의약품 시장 분석 : 유통 채널별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이·예측
• 병원
• 소매 약국
• 전문 약국
  • 시장 규모 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제6장 특수 의약품 시장 분석 : 치료제별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이·예측
• 종양
• 면역
• 당뇨병
• 순환기 질환
• 호흡기
• 중추신경계
• 기타
  • 시장 규모 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제7장 특수 의약품 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추이·예측

제8장 북미의 특수 의약품 시장의 분석

제9장 유럽의 특수 의약품 시장의 분석

제10장 아시아태평양의 특수 의약품 시장의 분석

제11장 라틴아메리카의 특수 의약품 시장의 분석

제12장 중동 및 아프리카의 특수 의약품 시장의 분석

제13장 기업 개요

• 경쟁 구도
• 전략적 전망
• CVS Health
• The Cigna Group
• UnitedHealth Group(Optum, Inc.)
• Walgreens Boots Alliance, Inc.
• Humana
• Teva Pharmaceutical Industries Ltd.
• Endo, Inc.
• AbbVie
• AstraZeneca
• Amgen Inc.
• Viatris Inc.
• Johnson &Johnson
• Sun Pharmaceutical Industries Ltd.
• Soleo Health
• Lumicera

제14장 결론·제안

• Visiongain으로부터의 결론
• 시장 참여 기업에 대한 제안

영문목차

The global Specialty Pharma market is projected to grow at a CAGR of 7.5% by 2034

The Specialty Pharma Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Digital Technology and AI Driving Industry Growth

In the realm of specialty pharma, the integration of digital technology and artificial intelligence (AI) promises a profound transformation. Embracing advanced IT platforms and AI-driven solutions empowers companies to enhance operational efficiency, accelerate time-to-market for biopharmaceutical products, and foster unprecedented levels of innovation. Automated workflows and real-time data analytics enable agile decision-making, enabling firms to swiftly capitalize on emerging market opportunities.

A robust IT infrastructure facilitates seamless collaboration across global teams and stakeholders, leveraging cloud-based solutions for secure data sharing and streamlined knowledge exchange. Personalized dashboards and mobile applications elevate client engagement by delivering real-time insights and actionable intelligence. This proactive approach not only enhances customer relationships but also positions companies competitively in a dynamic marketplace.

Moreover, digitalization enables predictive analytics and machine learning algorithms to optimize supply chain management and resource allocation, ensuring smoother operations and cost efficiencies. Virtual clinical trials and telemedicine platforms leverage digital advancements to improve patient recruitment, engagement, and overall trial outcomes, ultimately accelerating the delivery of innovative therapies to market.

As specialty pharma embraces digital transformation, the industry stands poised to unlock new levels of efficiency, innovation, and market expansion. Embracing these technologies not only meets current demands but also prepares companies to navigate future challenges with agility and foresight, shaping a resilient and forward-looking specialty pharma landscape.

Rising Specialty Drug Costs Likely to Challenge Industry Growth

The rising cost of specialty drugs poses a significant challenge to the growth of the specialty drugs market. These medications, often developed for complex and rare conditions, come with hefty price tags that can strain healthcare systems and patients alike. Recent examples highlight these concerns vividly. Firstly, Biogen's Alzheimer's drug, Aduhelm, priced at US$56,000 annually, sparked controversy over its affordability and potential impact on healthcare budgets. Despite its FDA approval, questions persist about whether its benefits justify the high cost.

Similarly, Eisai and Biogen's Leqembi, another Alzheimer's drug priced at $26,500 per year, faces scrutiny for its financial burden on Medicare beneficiaries and the healthcare system. The drug's cost, coupled with its modest efficacy, has raised doubts about its widespread adoption and long-term sustainability.

Moreover, the broader issue of specialty drug pricing extends beyond Alzheimer's treatments. Medications like Entresto, crucial for heart failure patients, also come at significant costs, influencing healthcare expenditure patterns and patient access. These examples underscore the broader challenge facing the specialty drugs market: balancing innovation and access with affordability. As these drugs promise breakthrough treatments for severe conditions, their high prices often limit accessibility, potentially depriving patients of life-changing therapies.

Addressing this challenge requires careful consideration of pricing strategies, reimbursement mechanisms, and policies that ensure equitable access without compromising innovation incentives. Stakeholders, including pharmaceutical companies, policymakers, and insurers, must collaborate to find sustainable solutions that promote both medical progress and patient welfare in an increasingly complex healthcare landscape.

What Questions Should You Ask before Buying a Market Research Report?

How is the Specialty Pharma market evolving?

What is driving and restraining the Specialty Pharma market?

How will each Specialty Pharma submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Specialty Pharma submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Specialty Pharma markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Specialty Pharma projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Specialty Pharma projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Specialty Pharma market?

Where is the Specialty Pharma market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Specialty Pharma market today, and over the next 10 years:

Our 264-page report provides 102 tables and 171 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Specialty Pharma prices and recent developments.

Segments Covered in the Report

Route of Administration

Oral

Parenteral

Rectal

Distribution Channel

Hospitals

Retail Pharmacies

Specialty Pharmacies

Therapeutics

Oncology

Cervical Cancer

Prostate Cancer

Others

Immunology

Arthritis

Crohn's Disease

Ulcerative Colitis

Others

Diabetes

Type 2 Diabetes (Non-insulin)

Type 1 Diabetes & Others

Cardiovascular Disease

Hypertension

Hyperlipidemia

Others

Respiratory

Asthma

COPD

Others

CNS

Neurovascular Diseases

Neurodegenerative Diseases

Mental Health

Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Specialty Pharma Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

AbbVie

Amgen Inc.

AstraZeneca

CVS Health

Endo, Inc.

Humana

Johnson & Johnson

Lumicera

Soleo Health

Sun Pharmaceutical Industries Ltd.

The Cigna Group

Teva Pharmaceutical Industries Ltd.

UnitedHealth Group (Optum, Inc.)

Viatris Inc.

Walgreens Boots Alliance, Inc.

Overall world revenue for Specialty Pharma Market, 2024 to 2034 in terms of value the market will surpass US$330 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Specialty Pharma Market, 2024 to 2034 report help you?

In summary, our 260+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Specialty Pharma Market, 2024 to 2034 Market, with forecasts for route of administration, therapeutics, and distribution channel each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Specialty Pharma Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Specialty Pharma Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Specialty Pharma Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Specialty Pharma Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
• 3.3 Impact Analysis
  • 3.3.1 Market Driving Factors
    • 3.3.1.1 Specialty Pharmaceutical Market Surges in Global Spending Landscape
    • 3.3.1.2 Immunology Market Surge Fuels Specialty Pharmaceuticals Growth
    • 3.3.1.3 Expanding Oncology Drug Demand Shapes Specialty Pharma Market Growth
  • 3.3.2 Market Restraining Factors
    • 3.3.2.1 Challenges of Rising Specialty Drug Costs in Healthcare
    • 3.3.2.2 The Impact of High Drug Costs on Insurance and Specialty Markets
  • 3.3.3 Market Opportunities
    • 3.3.3.1 Advanced Therapies and Innovation Fuelling Specialty Pharma Market Growth
    • 3.3.3.2 Specialty Pharma Seizes Growth Opportunity in Chronic and Rare Diseases
• 3.4 Supply Chain Analysis
• 3.5 Regulatory Framework
• 3.6 Emerging Markets and Megatrends
• 3.7 Porter's Five Forces Analysis
  • 3.7.1 Bargaining Power of Suppliers
  • 3.7.2 Bargaining Power of Buyers
  • 3.7.3 Competitive Rivalry
  • 3.7.4 Threat of Substitutes
  • 3.7.5 Threat of New Entrants
• 3.8 PEST Analysis

4 Specialty Pharma Market Analysis Route of Administration

• 4.1 Key Findings
• 4.2 Route of Administration Segment: Market Attractiveness Index
• 4.3 Specialty Pharma Market Size Estimation and Forecast by Route of Administration
• 4.4 Oral
  • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.4.2 Market Share by Region, 2024 & 2034 (%)
• 4.5 Parenteral
  • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.5.2 Market Share by Region, 2024 & 2034 (%)
• 4.6 Rectal
  • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 Specialty Pharma Market Analysis Distribution Channel

• 5.1 Key Findings
• 5.2 Distribution Channel Segment: Market Attractiveness Index
• 5.3 Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
• 5.4 Hospitals
  • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.4.2 Market Share by Region, 2024 & 2034 (%)
• 5.5 Retail Pharmacies
  • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.5.2 Market Share by Region, 2024 & 2034 (%)
• 5.6 Specialty Pharmacies
  • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.6.2 Market Share by Region, 2024 & 2034 (%)

6 Specialty Pharma Market Analysis by Therapeutics

• 6.1 Key Findings
• 6.2 Therapeutics Segment: Market Attractiveness Index
• 6.3 Specialty Pharma Market Size Estimation and Forecast by Therapeutics
• 6.4 Oncology
  • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.4.3 Oncology Market Size by Type
    • 6.4.3.1 Cervical Cancer
    • 6.4.3.2 Prostate Cancer
    • 6.4.3.3 Others
• 6.5 Immunology
  • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5.3 Immunology Market Size by Type
    • 6.5.3.1 Arthritis
    • 6.5.3.2 Crohn's Disease
    • 6.5.3.3 Ulcerative Colitis
    • 6.5.3.4 Others
• 6.6 Diabetes
  • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.6.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6.3 Diabetes Market Size by Type
    • 6.6.3.1 Type 2 Diabetes (Non-insulin)
    • 6.6.3.2 Type 1 Diabetes & Others
• 6.7 Cardiovascular Disease
  • 6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.7.2 Market Share by Region, 2024 & 2034 (%)
  • 6.7.3 Cardiovascular Disease Market Size by Type
    • 6.7.3.1 Hypertension
    • 6.7.3.2 Hyperlipidaemia
    • 6.7.3.3 Others
• 6.8 Respiratory
  • 6.8.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.8.2 Market Share by Region, 2024 & 2034 (%)
  • 6.8.3 Respiratory Market Size by Type
    • 6.8.3.1 Asthma
    • 6.8.3.2 COPD
    • 6.8.3.3 Others
• 6.9 CNS
  • 6.9.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.9.2 Market Share by Region, 2024 & 2034 (%)
  • 6.9.3 CNS Market Size by Type
    • 6.9.3.1 Neurovascular Diseases
    • 6.9.3.2 Neurodegenerative Diseases
    • 6.9.3.3 Mental Health
• 6.10 Others
  • 6.10.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.10.2 Market Share by Region, 2024 & 2034 (%)

7 Specialty Pharma Market Analysis by Region

• 7.1 Key Findings
• 7.2 Regional Market Size Estimation and Forecast

8 North America Specialty Pharma Market Analysis

• 8.1 Key Findings
• 8.2 North America Specialty Pharma Market Attractiveness Index
• 8.3 North America Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 8.4 North America Specialty Pharma Market Size Estimation and Forecast by Country
• 8.5 North America Specialty Pharma Market Size Estimation and Forecast by Route of Administration
• 8.6 North America Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
• 8.7 North America Specialty Pharma Market Size Estimation and Forecast by Therapeutics
• 8.8 U.S. Specialty Pharma Market Analysis
• 8.9 Canada Specialty Pharma Market Analysis

9 Europe Specialty Pharma Market Analysis

• 9.1 Key Findings
• 9.2 Europe Specialty Pharma Market Attractiveness Index
• 9.3 Europe Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 9.4 Europe Specialty Pharma Market Size Estimation and Forecast by Country
• 9.5 Europe Specialty Pharma Market Size Estimation and Forecast by Route of Administration
• 9.6 Europe Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
• 9.7 Europe Specialty Pharma Market Size Estimation and Forecast by Therapeutics
• 9.8 Germany Specialty Pharma Market Analysis
• 9.9 France Specialty Pharma Market Analysis
• 9.10 UK Specialty Pharma Market Analysis
• 9.11 Italy Specialty Pharma Market Analysis
• 9.12 Spain Specialty Pharma Market Analysis
• 9.13 Rest of Europe Specialty Pharma Market Analysis

10 Asia Pacific Specialty Pharma Market Analysis

• 10.1 Key Findings
• 10.2 Asia Pacific Specialty Pharma Market Attractiveness Index
• 10.3 Asia Pacific Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 10.4 Asia Pacific Specialty Pharma Market Size Estimation and Forecast by Country
• 10.5 Asia Pacific Specialty Pharma Market Size Estimation and Forecast by Route of Administration
• 10.6 Asia Pacific Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
• 10.7 Asia Pacific Specialty Pharma Market Size Estimation and Forecast by Therapeutics
• 10.8 Japan Specialty Pharma Market Analysis
• 10.9 China Specialty Pharma Market Analysis
• 10.10 India Specialty Pharma Market Analysis
• 10.11 Australia Specialty Pharma Market Analysis
• 10.12 South Korea Specialty Pharma Market Analysis
• 10.13 Rest of Asia Pacific Specialty Pharma Market Analysis

11 Latin America Specialty Pharma Market Analysis

• 11.1 Key Findings
• 11.2 Latin America Specialty Pharma Market Attractiveness Index
• 11.3 Latin America Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 11.4 Latin America Specialty Pharma Market Size Estimation and Forecast by Country
• 11.5 Latin America Specialty Pharma Market Size Estimation and Forecast by Route of Administration
• 11.6 Latin America Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
• 11.7 Latin America Specialty Pharma Market Size Estimation and Forecast by Therapeutics
• 11.8 Brazil Specialty Pharma Market Analysis
• 11.9 Mexico Specialty Pharma Market Analysis
• 11.10 Rest of Latin America Specialty Pharma Market Analysis

12 MEA Specialty Pharma Market Analysis

• 12.1 Key Findings
• 12.2 MEA Specialty Pharma Market Attractiveness Index
• 12.3 MEA Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 12.4 MEA Specialty Pharma Market Size Estimation and Forecast by Country
• 12.5 MEA Specialty Pharma Market Size Estimation and Forecast by Route of Administration
• 12.6 MEA Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
• 12.7 MEA Specialty Pharma Market Size Estimation and Forecast by Therapeutics
• 12.8 GCC Specialty Pharma Market Analysis
• 12.9 South Africa Specialty Pharma Market Analysis
• 12.10 Rest of MEA Specialty Pharma Market Analysis

13 Company Profiles

• 13.1 Competitive Landscape, 2023
• 13.2 Strategic Outlook
• 13.3 CVS Health
  • 13.3.1 Company Snapshot
  • 13.3.2 Company Overview
  • 13.3.3 Financial Analysis
    • 13.3.3.1 Net Revenue, 2019-2023
    • 13.3.3.2 Business Segment Market Shares, 2023
  • 13.3.4 Product Benchmarking
  • 13.3.5 SWOT Analysis
• 13.4 The Cigna Group
  • 13.4.1 Company Snapshot
  • 13.4.2 Company Overview
  • 13.4.3 Financial Analysis
    • 13.4.3.1 Net Revenue, 2019-2023
    • 13.4.3.2 Business Segment Market Shares, 2023
  • 13.4.4 Product Benchmarking
  • 13.4.5 SWOT Analysis
• 13.5 UnitedHealth Group (Optum, Inc.)
  • 13.5.1 Company Snapshot
  • 13.5.2 Company Overview
  • 13.5.3 Financial Analysis
    • 13.5.3.1 Net Revenue, 2019-2023
    • 13.5.3.2 Business Segment Market Shares, 2023
  • 13.5.4 Product Benchmarking
  • 13.5.5 Strategic Outlook
  • 13.5.6 SWOT Analysis
• 13.6 Walgreens Boots Alliance, Inc.
  • 13.6.1 Company Snapshot
  • 13.6.2 Company Overview
  • 13.6.3 Financial Analysis
    • 13.6.3.1 Net Revenue, 2019-2023
    • 13.6.3.2 Regional Market Shares, 2023
    • 13.6.3.3 Business Segment Market Shares, 2023
  • 13.6.4 Product Benchmarking
  • 13.6.5 Strategic Outlook
  • 13.6.6 SWOT Analysis
• 13.7 Humana
  • 13.7.1 Company Snapshot
  • 13.7.2 Company Overview
  • 13.7.3 Financial Analysis
    • 13.7.3.1 Net Revenue, 2019-2023
    • 13.7.3.2 Business Segment Market Shares, 2023
  • 13.7.4 Product Benchmarking
• 13.8 Teva Pharmaceutical Industries Ltd.
  • 13.8.1 Company Snapshot
  • 13.8.2 Company Overview
  • 13.8.3 Financial Analysis
    • 13.8.3.1 Net Revenue, 2019-2023
    • 13.8.3.2 R&D, 2019-2023
    • 13.8.3.3 Regional Market Shares, 2023
  • 13.8.4 Product Benchmarking
  • 13.8.5 Strategic Outlook
• 13.9 Endo, Inc.
  • 13.9.1 Company Snapshot
  • 13.9.2 Company Overview
  • 13.9.3 Product Benchmarking
• 13.10 AbbVie
  • 13.10.1 Company Snapshot
  • 13.10.2 Company Overview
  • 13.10.3 Financial Analysis
    • 13.10.3.1 Net Revenue, 2019-2023
    • 13.10.3.2 R&D, 2019-2023
    • 13.10.3.3 Regional Market Shares, 2023
    • 13.10.3.4 Business Segment Market Shares, 2023
  • 13.10.4 Product Benchmarking
  • 13.10.5 Strategic Outlook
• 13.11 AstraZeneca
  • 13.11.1 Company Snapshot
  • 13.11.2 Company Overview
  • 13.11.3 Financial Analysis
    • 13.11.3.1 Net Revenue, 2019-2023
    • 13.11.3.2 R&D, 2019-2023
    • 13.11.3.3 Regional Market Shares, 2023
  • 13.11.4 Product Benchmarking
• 13.12 Amgen Inc.
  • 13.12.1 Company Snapshot
  • 13.12.2 Company Overview
  • 13.12.3 Financial Analysis
    • 13.12.3.1 Net Revenue, 2019-2023
    • 13.12.3.2 R&D, 2019-2023
    • 13.12.3.3 Regional Market Shares, 2023
  • 13.12.4 Product Benchmarking
  • 13.12.5 Strategic Outlook
• 13.13 Viatris Inc.
  • 13.13.1 Company Snapshot
  • 13.13.2 Company Overview
  • 13.13.3 Financial Analysis
    • 13.13.3.1 Net Revenue, 2019-2023
    • 13.13.3.2 R&D, 2019-2023
    • 13.13.3.3 Regional Market Shares, 2023
  • 13.13.4 Product Benchmarking
• 13.14 Johnson & Johnson
  • 13.14.1 Company Snapshot
  • 13.14.2 Company Overview
  • 13.14.3 Financial Analysis
    • 13.14.3.1 Net Revenue, 2019-2023
    • 13.14.3.2 R&D, 2019-2023
    • 13.14.3.3 Regional Market Shares, 2023
    • 13.14.3.4 Business Segment Market Shares, 2023
  • 13.14.4 Product Benchmarking
• 13.15 Sun Pharmaceutical Industries Ltd.
  • 13.15.1 Company Snapshot
  • 13.15.2 Company Overview
  • 13.15.3 Financial Analysis
    • 13.15.3.1 Net Revenue, 2020-2024
  • 13.15.4 Product Benchmarking
  • 13.15.5 Strategic Outlook
• 13.16 Soleo Health
  • 13.16.1 Company Snapshot
  • 13.16.2 Company Overview
  • 13.16.3 Product Benchmarking
  • 13.16.4 Strategic Outlook
• 13.17 Lumicera
  • 13.17.1 Company Snapshot
  • 13.17.2 Company Overview
  • 13.17.3 Product Benchmarking

14 Conclusion and Recommendations

• 14.1 Concluding Remarks from Visiongain
• 14.2 Recommendations for Market Players